Clinical trials
Observational Hypertension trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Recruiting | 6 |
| Unknown status | 6 |
| Active, not recruiting | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boryung Pharmaceutical Co., Ltd | 8 |
| AstraZeneca | 7 |
| Daewoong Pharmaceutical Co. LTD. | 5 |
| Boehringer Ingelheim | 4 |
| DongGuk University | 2 |
| Handok Inc. | 2 |
| Hanmi Pharmaceutical Company Limited | 2 |
| A.Menarini Asia-Pacific Holdings Pte Ltd | 1 |
| Ahn-Gook Pharmaceuticals Co.,Ltd | 1 |
| Dongtan Sacred Heart Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 45 |
| Dyslipidemias | 7 |
| Diabetes Mellitus | 3 |
| Essential Hypertension | 3 |
| Hyperlipidemias | 2 |
| Arteriosclerosis | 1 |
| Atrioventricular Block | 1 |
| Coronary Vasospasm | 1 |
| Edema | 1 |
| Heart Failure | 1 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.